MyFinsight
Home
Blog
About
Net income (loss)
$80,080K
(134.53%↑ Y/Y)
Stock-based compensation
$12,391K
(-53.26%↓ Y/Y)
Accounts payable
$12,309K
(65.35%↑ Y/Y)
Accrued liabilities and
other liabilities
$8,392K
(253.76%↑ Y/Y)
Prepaid expenses and
other current assets
-$5,677K
(4.38%↑ Y/Y)
Depreciation and
amortization
$2,802K
(-51.56%↓ Y/Y)
Change in fair value of
equity investments
$1,723K
(157.43%↑ Y/Y)
Issuance of common
stock-Public Offering
$162,205K
Noncash lease expense
$1,369K
(-41.94%↓ Y/Y)
Change in estimated
fair value of...
$1,130K
(-89.74%↓ Y/Y)
Amortization of premiums on
investments, net
-$322K
(95.13%↑ Y/Y)
Other non-cash items,
net
$41K
(-30.51%↓ Y/Y)
Issuance of common
stock-Astellas Pharma Inc.
$75,724K
Proceeds from exercise of
stock options
$1,440K
(15.48%↑ Y/Y)
Proceeds from issuance of
common stock under espp
$1,356K
(-22.82%↓ Y/Y)
Net cash used in
operating activities
$123,326K
(162.18%↑ Y/Y)
Net cash provided by
financing activities
$78,376K
(2864.30%↑ Y/Y)
Canceled cashflow
$2,910K
Canceled cashflow
$162,349K
Net increase
(decrease) in cash, cash...
$4,560K
(136.72%↑ Y/Y)
Canceled cashflow
$197,142K
Operating lease
liabilities
-$2,306K
(29.11%↑ Y/Y)
Other assets
$604K
(-46.64%↓ Y/Y)
Maturities and sales of
investments
$154,989K
(-71.98%↓ Y/Y)
something is missing
-$162,349K
Net cash (used in)
provided by investing...
-$197,142K
(-207.57%↓ Y/Y)
Canceled cashflow
$154,989K
Purchases of investments
$352,099K
(-3.82%↓ Y/Y)
Purchases of long-lived
assets
$32K
(-99.23%↓ Y/Y)
Back
Back
Cash Flow
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)
source: myfinsight.com